CFHR5
Complement factor H-related protein 5
Also known as: CFHL5, FHR-5, FHR5, FHR5_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9BXR6
- Gene
- CFHR5
- Ensembl
- ENSG00000134389
- Chromosome
- 1
- Canonical length
- 569 aa
- Protein class
- Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene is a member of a small complement factor H (CFH) gene cluster on chromosome 1. Each member of this gene family contains multiple short consensus repeats (SCRs) typical of regulators of complement activation. The protein encoded by this gene has nine SCRs with the first two repeats having heparin binding properties, a region within repeats 5-7 having heparin binding and C reactive protein binding properties, and the C-terminal repeats being similar to a complement component 3 b (C3b) binding domain. This protein co-localizes with C3, binds C3b in a dose-dependent manner, and is recruited to tissues damaged by C-reactive protein. Allelic variations in this gene have been associated, but not causally linked, with two different forms of kidney disease: membranoproliferative glomerulonephritis type II (MPGNII) and hemolytic uraemic syndrome (HUS). [provided by RefSeq, Jan 2010]
Canonical amino-acid sequenceUniProt
569 residues, UniProt reviewed canonical sequence.
>Q9BXR6|CFHR5
1 MLLLFSVILI SWVSTVGGEG TLCDFPKIHH GFLYDEEDYN PFSQVPTGEV FYYSCEYNFV
61 SPSKSFWTRI TCTEEGWSPT PKCLRMCSFP FVKNGHSESS GLIHLEGDTV QIICNTGYSL
121 QNNEKNISCV ERGWSTPPIC SFTKGECHVP ILEANVDAQP KKESYKVGDV LKFSCRKNLI
181 RVGSDSVQCY QFGWSPNFPT CKGQVRSCGP PPQLSNGEVK EIRKEEYGHN EVVEYDCNPN
241 FIINGPKKIQ CVDGEWTTLP TCVEQVKTCG YIPELEYGYV QPSVPPYQHG VSVEVNCRNE
301 YAMIGNNMIT CINGIWTELP MCVATHQLKR CKIAGVNIKT LLKLSGKEFN HNSRIRYRCS
361 DIFRYRHSVC INGKWNPEVD CTEKREQFCP PPPQIPNAQN MTTTVNYQDG EKVAVLCKEN
421 YLLPEAKEIV CKDGRWQSLP RCVESTAYCG PPPSINNGDT TSFPLSVYPP GSTVTYRCQS
481 FYKLQGSVTV TCRNKQWSEP PRCLDPCVVS EENMNKNNIQ LKWRNDGKLY AKTGDAVEFQ
541 CKFPHKAMIS SPPFRAICQE GKFEYPICELocalizationUniProt · AlphaFold · HPA
Whether an antibody against CFHR5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.33
- Highest tissue expression
- 156 nTPM
Expression across tissuesHPA
Tissue
- liver: 156 nTPM
- adipose tissue: 0 nTPM
- adrenal gland: 0 nTPM
- amygdala: 0 nTPM
- appendix: 0 nTPM
- basal ganglia: 0 nTPM
Single-cell type
- hepatocytes: 125 nCPM
- kupffer cells: 4.1 nCPM
- gastric chief cells: 1.1 nCPM
- granulosa cells: 0.8 nCPM
- undifferentiated spermatogonia: 0.7 nCPM
- late spermatids: 0.6 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
- cerebral cortex: 0 nTPM
- choroid plexus: 0 nTPM
- hippocampal formation: 0 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about CFHR5.
Disease | AllUniProt
Conditions CFHR5 is implicated in, by any mechanism.
- CFHR5 deficiency (CFHR5D) MIM:614809
Disease | GeneticClinVar
2 pathogenic / likely-pathogenic of 367 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
Disease | ImmuneIEDB
Conditions an epitope on CFHR5 was assayed in.
- rheumatoid arthritis B cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.83
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.9
- DepMap mean gene effect
- 0.1
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- complement activation
- complement activation, alternative pathway
- cytolysis by host of symbiont cells
- negative regulation of protein binding
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CFHR5 as an antibody target. Whether an autoantibody or antibody against CFHR5 could matter depends on whether native CFHR5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CFHR5 is annotated as secreted, so native CFHR5 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label CFHR5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...